News & Views
Key Technology Patents Granted in Japan
Aug 07 2015
Patents covering the technology of assays used for evaluating a patient's immune system, have been granted to ImmunID for markets in Japan, United States, Europe and Canada. ImmunTraCkeR® has demonstrated clinical utility predicting response to immuno-oncology therapies and is currently under further validation for prediction of response and monitoring of cancer patients under treatment with immune checkpoint inhibitors.
The two patent families (WO2005056828 and WO2009095567) cover the multi-N-plex® Polymerase Chain Reaction (PCR) technology underlying the ImmunTraCkeR® and ImmunIG® assays.
"The immune system plays a fundamental role in diseases, which is why monitoring it is essential. As a pioneer in the field of immune molecular diagnostics for a decade, ImmunID has filed multiple patent applications covering clinical applications of its immune assays in immunotherapy, cancer and infections," explained Nicolas Pasqual, Chief Scientific Officer, and Sebastien Weisbuch, Chief Operating Officer, both co-founders of ImmunID.
"Our IP strategy focuses on ring-fencing the technology of our assays while securing the emerging clinical value. This combination creates the commercial value crucial to attract high quality investors and the funds needed to allow further validation and identification of new clinical utility for our assays," added Bernhard Sixt, ImmunID's Chairman and Chief Executive Officer.
Digital Edition
Lab Asia 31.4 August 2024
August 2024
Chromatography Articles - HPLC gradient validation using non-invasive flowmeters Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers Labo...
View all digital editions
Events
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Bangkok, Thailand
Sep 11 2024 Singapore
Sep 18 2024 Lausanne, Switzerland
Sep 19 2024 Shanghai, China